KRYS
Krystal Biotech Inc
NASDAQ · Biotechnology
$272.74
+5.10 (+1.91%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 283.26M | 971.92M | 894.90M | 986.11M |
| Net Income | 86.93M | 120.52M | 102.54M | 123.97M |
| EPS | — | — | — | — |
| Profit Margin | 30.7% | 12.4% | 11.5% | 12.6% |
| Rev Growth | — | +7.7% | -5.6% | +0.5% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 2.99B | 2.71B | 2.84B |
| Total Equity | — | 5.06B | 4.99B | 5.78B |
| D/E Ratio | — | 0.59 | 0.54 | 0.49 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | 69.87M | 242.82M | 232.68M | 229.91M |
| Free Cash Flow | — | 82.52M | 69.44M | 100.58M |